JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms.

@article{Schnberg2015JAKII,
  title={JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms.},
  author={Kathrin Sch{\"o}nberg and Janna Rudolph and Maria Vonnahme and Sowmya Parampalli Yajnanarayana and Isabelle Cornez and Maryam Hejazi and Angela R. Manser and Markus Uhrberg and W. H. J. Verbeek and Steffen Koschmieder and Tim H. Br{\"u}mmendorf and Peter Brossart and Annkristin Heine and Dominik Georg Friedrich Wolf},
  journal={Cancer research},
  year={2015},
  volume={75 11},
  pages={2187-99}
}
Ruxolitinib is a small-molecule inhibitor of the JAK kinases, which has been approved for the treatment of myelofibrosis, a rare myeloproliferative neoplasm (MPN), but clinical trials are also being conducted in inflammatory-driven solid tumors. Increased infection rates have been reported in ruxolitinib-treated patients, and natural killer (NK) cells are immune effector cells known to eliminate both virus-infected and malignant cells. On this basis, we sought to compare the effects of JAK… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS
43 Citations
55 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 55 references

Ruxolitinib mediated paradox JAK2 hyperphosphorylation is due to the protection of activation loop phosphotyrosines from phosphatases

  • SP BKGorantla, AL Illert, N von Bubnoff, C Peschel, J. Duyster
  • ASH
  • 2013
Highly Influential
5 Excerpts

A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC)

  • H Hurwitz, N Uppal, SA Wagner, JC Bendell, JT Beck, S Wade
  • J Clin Oncol 2014;32:5s,
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…